trospectomycin
active against Neisseria gonorrhoeae; RN refers to 2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9beta,9alpha,9aalpha,10abeta)-(9CI)-isomer
Also Known As:
U 63366; U 63366f; U-63366; trospectomycin sulfate; trospectomycin sulphate
Networked: 19
relevant articles (3 outcomes,
2 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Related Diseases
1. | Gonorrhea
07/01/1994
- " Among evaluable male patients with urethral gonorrhea, 36 of 40 (90%, 95% confidence interval [95%CI] 76%-97%) who were treated with trospectomycin sulfate were cured, and 22 of 22 patients (100%, [85%-100%]) treated with ceftriaxone were cured. " 07/01/1994
- " Among evaluable female patients with cervical gonorrhea all were cured following trospectomycin sulfate (23 of 23) and following ceftriaxone therapy (13 of 13). " 07/01/1994
- " The cure rates for pharyngeal gonorrhea were 67% (8 of 12 patients, 35%-90%) for trospectomycin sulfate therapy, and 100% (2 of 2) with ceftriaxone therapy. " 07/01/1992
- " Trospectomycin sulfate (trospectomycin, TRS) is a novel, broad-spectrum, aminocyclitol antibiotic that is being developed clinically for the treatment of upper respiratory tract infections, bacterial vaginosis, pelvic inflammatory disease, and gonorrhea. "
|
2. | Reproductive Tract Infections
|
3. | Endometritis
|
4. | Infections
|
5. | Pelvic Inflammatory Disease (Pelvic Inflammatory Diseases)
|
|
Related Drugs and Biologics
Related Therapies and Procedures